2021
How to prevent and manage hyperammonemic encephalopathies in valproate therapy
Mitschek M, Vanicek T, Unterholzner J, Kraus C, Weidenauer A, Naderi-Heiden A, Frey R, Silberbauer L, Gryglewski G, Papageorgiou K, Winkler D, Dold M, Kasper S, Praschak-Rieder N, Bartova L. How to prevent and manage hyperammonemic encephalopathies in valproate therapy. Journal Of Affective Disorders Reports 2021, 5: 100186. DOI: 10.1016/j.jadr.2021.100186.Peer-Reviewed Case Reports and Technical NotesSevere cognitive impairmentValproic acidHyperammonemic encephalopathyPlasma levelsCognitive impairmentPotential drug interactionsYoung male patientLife-threatening symptomsUrea cycle deficiencyUrea cycle defectsValproate therapyMale patientsCase seriesFemale patientsUrinary levelsComatose stateDrug interactionsIndividual patientsPsychotic episodePatientsAffective symptomsCurrent psychotic episodePsychiatric inpatientsPolypharmacyEncephalopathy
2019
Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging
Gryglewski G, Klöbl M, Berroterán-Infante N, Rischka L, Balber T, Vanicek T, Pichler V, Kautzky A, Klebermass EM, Reed MB, Vraka C, Hienert M, James GM, Silberbauer L, Godbersen GM, Unterholzner J, Michenthaler P, Hartenbach M, Winkler-Pjrek E, Wadsak W, Mitterhauser M, Hahn A, Hacker M, Kasper S, Lanzenberger R. Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging. European Neuropsychopharmacology 2019, 29: 711-719. PMID: 31076187, DOI: 10.1016/j.euroneuro.2019.04.001.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitorsReuptake inhibitorsPharmacological responsePharmacological imagingFunctional MRIRandomized double-blind designResting-state functional MRIAcute pharmacological responsesCitalopram plasma concentrationsPrevalent neuropsychiatric conditionsDouble-blind designMechanism of actionPlacebo scansInfusion paradigmPlasma levelsSSRI effectsDrug challengePatient outcomesPlasma concentrationsDrug infusionInfluence treatmentConstant infusionLarger sample sizePET/MR scans
2017
Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography
Spies M, James GM, Berroterán-Infante N, Ibeschitz H, Kranz GS, Unterholzner J, Godbersen M, Gryglewski G, Hienert M, Jungwirth J, Pichler V, Reiter B, Silberbauer L, Winkler D, Mitterhauser M, Stimpfl T, Hacker M, Kasper S, Lanzenberger R. Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography. The International Journal Of Neuropsychopharmacology 2017, 21: 145-153. PMID: 29045739, PMCID: PMC5793827, DOI: 10.1093/ijnp/pyx085.Peer-Reviewed Original ResearchConceptsKetamine plasma levelsPositron emission tomographyAntidepressant effectsPlasma levelsSerotonin transporterEmission tomographyAntidepressant dosePositron emission tomography scanReal-life patient cohortEmission tomography scanHigh-dose ketamineSerotonin transporter bindingTest-retest variabilityWhole brain regionsAntidepressant dosesAntidepressant mechanismPatient cohortTomography scanSerotonergic systemTransporter bindingHealthy subjectsAnimal studiesHigh dosesKetamineAdministration
2014
High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People
Kranz GS, Wadsak W, Kaufmann U, Savli M, Baldinger P, Gryglewski G, Haeusler D, Spies M, Mitterhauser M, Kasper S, Lanzenberger R. High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People. Biological Psychiatry 2014, 78: 525-533. PMID: 25497691, PMCID: PMC4585531, DOI: 10.1016/j.biopsych.2014.09.010.Peer-Reviewed Original ResearchConceptsSerotonin reuptake transporterSERT bindingFemale transsexualsStart of treatmentSteroid hormone treatmentNew treatment modalitiesTreatment of depressionMedian raphe nucleusHormone plasma levelsTreatment-induced increaseMid-cingulate cortexPositron emission tomographyMechanism of actionTreatment startSerotonergic transmissionEstradiol levelsRaphe nucleusEstrogen treatmentReuptake transporterTreatment modalitiesAndrogen treatmentEpidemiologic findingsPlasma levelsSex hormonesSERT expression